Riverside Internal Medicine Plc in Ascutney, VT - Internal Medicine

Riverside Internal Medicine Plc is a primary clinic (Internal Medicine) in Ascutney, Vermont. The current practice location for Riverside Internal Medicine Plc is 14 Ascutney Place, Unit B2, Ascutney, Vermont. For appointments, you can reach them via phone at (802) 674-6744. The mailing address for Riverside Internal Medicine Plc is Po Box 416, Ascutney, Vermont and phone number is (802) 674-6744.

Riverside Internal Medicine Plc is licensed to practice in * (Not Available) (license number ) and its NPI number is 1902864218. This medical practice does not participate in medicare program and thus may not accept your medicare insurance. You may check if they accept your insurance at (802) 674-6744.

Contact Information

	Riverside Internal Medicine Plc
	14 Ascutney Place Unit B2 Ascutney VT 05030
	(802) 674-6744
	(802) 674-6744

Primary Care Clinic Profile

Full Name	Riverside Internal Medicine Plc
Speciality	Internal Medicine
Location	14 Ascutney Place, Ascutney, Vermont
Authorized Official Name and Position	Sheila J Kendrick (MD OWNER)
Authorized Official Contact	8026746744
Accepts Medicare Insurance	This clinic does not participate in Medicare Program.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Riverside Internal Medicine Plc Po Box 416 Ascutney VT 05030 Ph: (802) 674-6744	Riverside Internal Medicine Plc 14 Ascutney Place Unit B2 Ascutney VT 05030 Ph: (802) 674-6744

NPI Details:

NPI Number	1902864218
Provider Enumeration Date	05/03/2006
Last Update Date	12/31/2012

Medical Identifiers

Medical identifiers for Riverside Internal Medicine Plc such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1902864218	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207R00000X	Internal Medicine	(* (Not Available))	Primary

News Archive

Viking successfully completes safety, tolerability and pharmacokinetic study of VK5211 in elderly subjects

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the successful completion of a short-term safety, tolerability, and pharmacokinetic study of VK5211 in healthy elderly subjects. VK5211, the company's lead program for muscle and bone disorders, is an orally available, non-steroidal selective androgen receptor modulator (SARM) being developed for the treatment of patients recovering from non-elective hip fracture surgery.

Neutralization approach appears to prevent proliferative vitreoretinopathy

Proliferative vitreoretinopathy (PVR), or the formation of scar tissue within the eye, is a serious, sight-threatening complication in patients recovering surgical repair of retinal detachment. A new study conducted by investigators at the Schepens Eye Research Institute, the Department of Ophthalmology at Harvard Medical School, and the Massachusetts Eye and Ear Infirmary in Boston, published in the December issue of the American Journal of Pathology, suggests that a cocktail containing reagents to neutralize a relatively small subset of vitreal growth factors and cytokines may be an effective treatment.

Patients with history of skin infection more likely to develop surgical site infections

Johns Hopkins scientists have engineered cells that behave like AND and OR Boolean logic gates, producing an output based on one or more unique inputs. This feat, published in the May issue of Nature Chemical Biology, could eventually help researchers create computers that use cells as tiny circuits.

Rapid and point-of-care tests accurate, convenient for hepatitis C screening

Rapid and point-of-care screening tests for hepatitis C have a high accuracy and quick turnaround time, suggest results of a systematic review and meta-analysis.

Riverside Internal Medicine Plc - Primary Care in Ascutney, VT